CHARACTERIZING DISEASE BURDEN IN AN ULTRA-RARE DISEASE IN THE U.S.- TRANSTHYRETIN (TTR) AMYLOIDOSIS PATIENTS & CAREGIVERS
Author(s)
Stewart M1, Loftus J*2, Lenderking WR3, Murphy BR3, Alvir J4, Roberts L5, Shaffer S5, Cicchetti MJ6, Gleeson S5 1Pfizer, Inc, Groton, CT, USA, 2Pfizer Ltd, Tadworth, United Kingdom, 3Evidera, Lexington, MA, USA, 4Pfizer, Inc., New York, NY, USA, 5Evidera, Bethesda, MD, USA, 6Pfizer, Inc., Groton, CT, USA
OBJECTIVES: TTR amyloidosis, a progressive, degenerative ultra-rare genetic disease, can cause familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-CM), requiring substantial caregiver support. This study evaluated the burden of illness on patients’ and caregivers’ work productivity, healthcare resource use (HCRU), and health-related quality of life (HRQoL). METHODS: An online survey including the Work Productivity & Activity Impairment (WPAI) questionnaire, EQ-5D, & HCRU questions recruited TTR-FAP and TTR-CM patients and caregivers through two U.S.-based patient advocacy groups. RESULTS: Thirty-three TTR patients (26 males) and 18 caregivers (7 males) completed the survey. Most were aged over 60; mean disease duration was approximately 6 years (patients) or 5 years (caregivers with disease). Most patients and caregivers had a college degree. Generally caregivers (77.8%) were the primary caregiver for their patient; 61.1% also had amyloidosis. Unemployment was high in patients with TTR-FAP (42.9%), TTR-CM (60.0%), both TTR-FAP/CM (71.4%); only 33.3% of caregivers reported working part/full-time. Employment was highest for TTR-FAP patients (n=10), yet 11.8% missed work, 32.2% were impaired at work and 38.5% reported overall work impairment due to TTR. Liver transplant, the primary treatment option, occurred in 42.4% patients and 18.2% caregivers with disease. A majority of patients reported outpatient visits to healthcare providers in the past 3 months for disease: 85.7% TTR-FAP, 100% TTR-CM, and 85.7% for TTR-FAP/CM. Hospitalization rates ranged from 14.3-30.0% across all patient groups, with 14.3-23.8% for emergency visits. EQ-5D Index scores for patients were 0.80 (SD=0.14) with transplant, and 0.68 (SD=0.16) without transplant. Caregivers with disease and transplant had lower EQ-5D Index scores (M=0.14, SD=0.35) than those without transplant (M=0.41, SD=0.32). The pattern was similar for EQ-5D VAS results for patient and caregiver groups. CONCLUSIONS: TTR amyloidosis is associated with substantial disruption in employment rates, work productivity, high levels of resource use, and poor HRQoL for patients and caregivers.
Conference/Value in Health Info
2013-11, ISPOR Europe 2013, The Convention Centre Dublin
Value in Health, Vol. 16, No. 7 (November 2013)
Code
PSY49
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Rare and Orphan Diseases